Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome

Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation... Coronary Heart Disease Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome Kai C. Wollert, MD; Tibor Kempf, MD; Timo Peter, BSc; Sylvia Olofsson, BSc; Stefan James, MD; Nina Johnston, MD; Bertil Lindahl, MD; Rüdiger Horn-Wichmann, BSc; Georg Brabant, MD; Maarten L. Simoons, MD; Paul W. Armstrong, MD; Robert M. Califf, MD; Helmut Drexler, MD; Lars Wallentin, MD Background—Growth-differentiation factor-15 (GDF-15) is a member of the transforming growth factor- cytokine superfamily that is induced in the heart after ischemia-and-reperfusion injury. Circulating levels of GDF-15 may provide prognostic information in patients with non–ST-elevation acute coronary syndrome. Methods and Results—Blood samples were obtained on admission from 2081 patients with acute chest pain and either ST-segment depression or troponin elevation who were included in the Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV Non–ST-Elevation Acute Coronary Syndrome trial and from a matching cohort of 429 apparently healthy individuals. GDF-15 levels were determined by immunoradiometric assay. Approximately two thirds of patients presented with GDF-15 levels above the upper limit of normal in healthy controls (1200 ng/L); one third presented with levels 1800 ng/L. Increasing tertiles of GDF-15 were associated with an enhanced risk of death at 1 year (1.5%, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome

Wallentin, Lars
Circulation , Volume 115 (8) – Feb 1, 2007
Download PDF
10 pages

Loading next page...
 
/lp/wolters-kluwer-health/prognostic-value-of-growth-differentiation-factor-15-in-patients-with-hhYyzuHOTT

References (18)

ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.106.650846
pmid
17283261
Publisher site
See Article on Publisher Site

Abstract

Coronary Heart Disease Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome Kai C. Wollert, MD; Tibor Kempf, MD; Timo Peter, BSc; Sylvia Olofsson, BSc; Stefan James, MD; Nina Johnston, MD; Bertil Lindahl, MD; Rüdiger Horn-Wichmann, BSc; Georg Brabant, MD; Maarten L. Simoons, MD; Paul W. Armstrong, MD; Robert M. Califf, MD; Helmut Drexler, MD; Lars Wallentin, MD Background—Growth-differentiation factor-15 (GDF-15) is a member of the transforming growth factor- cytokine superfamily that is induced in the heart after ischemia-and-reperfusion injury. Circulating levels of GDF-15 may provide prognostic information in patients with non–ST-elevation acute coronary syndrome. Methods and Results—Blood samples were obtained on admission from 2081 patients with acute chest pain and either ST-segment depression or troponin elevation who were included in the Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV Non–ST-Elevation Acute Coronary Syndrome trial and from a matching cohort of 429 apparently healthy individuals. GDF-15 levels were determined by immunoradiometric assay. Approximately two thirds of patients presented with GDF-15 levels above the upper limit of normal in healthy controls (1200 ng/L); one third presented with levels 1800 ng/L. Increasing tertiles of GDF-15 were associated with an enhanced risk of death at 1 year (1.5%,

Journal

Circulation – Wolters Kluwer Health

Published: Feb 1, 2007

There are no references for this article.